CD19 and neoplasm: Although CD19 CART cells induced the initial tumor remission, clinical trials have reported relapse rates of 21% to 45% following CART therapy despite a limited follow-up.[21] Relapse following CD19 CART therapy could be CD19+ or CD19–, and further therapy regimes have not been explicated.[22] CART therapy alone was insufficient for long-term survival.